KRAS and breast cancer: For example, the KRAS G13D–mutated breast cancer cell line (MDA-MB-231) and colorectal cancer cell line (NCI-H747) were sensitive to the SHP2 inhibitors SHP099 and TNO155, respectively (Ahmed et al., 2019; Liu et al., 2021).